| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 08/13/2009 | US20090202614 Methods for stepwise deposition of silk fibroin coatings |
| 08/13/2009 | US20090202575 Immunostimulatory nucleic acid molecules |
| 08/13/2009 | US20090202541 Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl)-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent |
| 08/13/2009 | US20090202442 Enerceutical activation of the alternative cellular energy (ACE) pathway in therapy of diseases |
| 08/13/2009 | US20090202438 Epitope regions of a thyrotrophin (tsh) receptor, uses thereof and antibodies thereto |
| 08/13/2009 | DE102008008522A1 Implantierbare Nanopartikel-enthaltende Produkte Implantable nanoparticle-containing products |
| 08/13/2009 | CA2715143A1 Novel phenylpyrrole derivative |
| 08/13/2009 | CA2714480A1 3,8-diaminotetrahydroquinoline derivative |
| 08/13/2009 | CA2713855A1 Benzylpiperizine compound |
| 08/13/2009 | CA2713786A1 Anti trka antibodies and derivatives thereof |
| 08/13/2009 | CA2711778A1 Pyrrolopyrimidine derivative as pi3k inhibitor and use thereof |
| 08/13/2009 | CA2711399A1 3-substituted sulfonylpiperidine derivative |
| 08/12/2009 | EP2088157A1 Collagen peptide composition and food or beverage containing the same |
| 08/12/2009 | EP2087899A1 Grifola frondosa-origin substance having antiinfluenza virus activity and method of producing the same |
| 08/12/2009 | EP2087892A2 (S,S) reboxetine for treating age associated learning and mental disorders |
| 08/12/2009 | EP2087891A2 Pharmaceutical compositions for treating lymphoma |
| 08/12/2009 | EP2086589A2 Ultrasound microbubble mediated genes delivery system |
| 08/12/2009 | EP2086568A2 Activated protein c variants with normal cytoprotective activity but reduced anticoagulant activity |
| 08/12/2009 | EP1998767A4 Method for promoting composite tissue regeneration and uses thereof |
| 08/12/2009 | EP1880733A4 Method for increasing longevity of a human being and animals |
| 08/12/2009 | EP1682121B1 Use of crth2 antagonist compounds in therapy |
| 08/12/2009 | EP1515959B1 Pharmaceutical salts of reboxetine |
| 08/12/2009 | EP1514116B1 Oxaliplatin anti-resistance method |
| 08/12/2009 | EP1509529B1 Esters in position 20 of camptothecins |
| 08/12/2009 | EP1469867B1 Method of treating halitosis |
| 08/12/2009 | EP1463735B1 Imidazo¬2,1-b -1,3,4-thiadiazole sulfonamides |
| 08/12/2009 | EP1416048B1 Nucleic acid participating in the formation of presenilin-2-gene exon 5-defective splicing variant |
| 08/12/2009 | EP1385514B9 Spiroindene and spiroindane compounds |
| 08/12/2009 | EP1379257B1 Prodrugs of anticancer agents employing substituted aromatic acids |
| 08/12/2009 | EP1343760B1 Muscarinic antagonists |
| 08/12/2009 | EP1294402B2 Compounds with a sulphonamide group and pharmaceutical compositions containing these compounds |
| 08/12/2009 | EP1290227B1 Compositions, kits, and methods for identification and modulation of type i diabetes |
| 08/12/2009 | EP1255813B1 Multipotent neural stem cells from mammalian skin and uses thereof |
| 08/12/2009 | EP1242105B3 Combination of ginseng and ginkgo to improve cognitive skills |
| 08/12/2009 | EP1149111B1 Method and composition for angiogenesis inhibition |
| 08/12/2009 | EP0898580B9 Methods and means for inhibition of cdk4 activity |
| 08/12/2009 | EP0788360B3 Boronic ester and acid compounds, synthesis and uses |
| 08/12/2009 | EP0674505B2 Synergistic combinations of active substance for the cosmetic or dermatological care of the skin, hair and nails |
| 08/12/2009 | CN101506170A 6-(heterocycle-substituted benzyl)-4-oxoquinoline compound and use of the same as HIV integrase inhibitor |
| 08/12/2009 | CN101506164A Piperidine derivatives |
| 08/12/2009 | CN101505800A Preparation of pegylated conjugates of VLA-4 antagonists via a Mitsunobu's reaction |
| 08/12/2009 | CN101505791A Diagnosis and treatment of cancer using anti-desmoglein-3 antibody |
| 08/12/2009 | CN101505788A Prophylactic and/or therapeutic agents for peripheral neuropathy |
| 08/12/2009 | CN101505761A Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases |
| 08/12/2009 | CN101505755A Agent for overcoming resistance to anti-cancer agent |
| 08/12/2009 | CN101503736A Use of retinoic acid induced gene I, signal pathway mediated by coding protein thereof |
| 08/12/2009 | CN101503409A 8-(3-amino-piperidin-1-yl)-xanthines, the production thereof and the use of the same as medicaments |
| 08/12/2009 | CN101503408A 8-(3-amino-piperidin-1-yl)-xanthines |
| 08/12/2009 | CN101503407A Imidazopyridine compound |
| 08/12/2009 | CN101503392A Aromatic aminomethane compounds, as well as preparation and medical use thereof |
| 08/12/2009 | CN101502527A Application of mulberroside in preparing medicament for inhibiting uric acid reabsorption transporter |
| 08/12/2009 | CN101502507A Egonol type benzofuran and novel use in pharmacy of glycosides thereof |
| 08/12/2009 | CN100526331C CTL epitopes from EBV |
| 08/12/2009 | CN100526307C Metalloproteinase inhibitors |
| 08/12/2009 | CN100525831C Improved pharmaceutical botulinum toxin compositions |
| 08/12/2009 | CN100525830C Process of preparation of formulations of the peptide angiotensin-(1-7) and its analogues, agonistic and antagonists using cyclodextrins, lipossomes and biodegradable polymers and/or mixtures and prod |
| 08/12/2009 | CN100525771C Medicine possessing menacme accerant contraception action |
| 08/12/2009 | CN100525768C Novel compounds |
| 08/12/2009 | CN100525766C (imidazol-5-yl)methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation |
| 08/12/2009 | CN100525763C Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage |
| 08/11/2009 | US7572924 Pyrrole substituted 2-indolinone protein kinase inhibitors |
| 08/11/2009 | US7572920 Benzimidazole derivative and use as a II receptor antagonist |
| 08/11/2009 | US7572900 Expression vector comprising breast cancer gene (BCL-2) nucleotide sequences for use as tool in treatment, diagnosis and prevention of cell proliferative disorders |
| 08/11/2009 | US7572886 Death associated proteins, and THAP1 and PAR4 pathways in apoptosis control |
| 08/11/2009 | US7572817 Carboxypeptidase U inhibitors; thrombosis, atherosclerosis, adhesions, dermal scarring, cancer, fibrotic conditions, inflammatory diseases; e.g. 2-[(6-Aminopyridin-3-yl)methyl]-3-mercapto-5-[3-(pyrrolidin-1-ylcarbonyl)phenyl]pentanoic acid |
| 08/11/2009 | US7572815 Amide derivative |
| 08/11/2009 | US7572813 Cyclic amide derivative as monocyte chemotactic protein modulator; prevention and treatment of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma; antiinflammatory agents; N-[2-[[(cis) -2-[[1- (4-Chlorophenyl)ethyl]amino]cyclohexyl]amino]-2-oxoethyl]-3-(trifluoromethyl)benzamide |
| 08/11/2009 | US7572796 excitatory amino acid antagonists for treating neurodegenerative diseases as cerebrovascular diseases, epilepsy, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, cerebral ischaemia, infarction, psychoses; 6-{3-[4-(4-fluorobenzyl)-1-piperidyl]propyl}-1H-indole-3-carbonitrile |
| 08/11/2009 | US7572793 Tau protein kinase 1 inhibitors; treatment for neurodegenerative disorders; Alzheimer's Disease, Parkinson's disease, Pick's Disease, vision defects; antiischemic, antidiabetic, anticarcinogenic, antitumor agents, antidepressants |
| 08/11/2009 | US7572791 Long-term stability, extended delivery using a suitable reservoir; pumped or metered at a controlled rate; implantable or external pump device, pen style injection device; stable at physiologic temperatures for duration of therapeutic exposure; supply of therapeutically active material for up to 2 years |
| 08/11/2009 | US7572787 Substituted naphthalene sulfonamides |
| 08/11/2009 | US7572774 Methods for treating glutamate cytotoxicity with beta-naphthoquinone compounds |
| 08/11/2009 | US7572762 Materials and methods relating to the induction of apoptosis in target cells |
| 08/11/2009 | US7572605 1,2,3,tris(4-hydroxy-butyroyloxy)propane; enhance the uptake of the drug, deliver effective therapeutic doses in a time-delayed fashion, and target specific organs |
| 08/11/2009 | US7572574 Method of measuring neprilysin activity |
| 08/11/2009 | US7572465 Isolated material having an anti-organotrophic effect |
| 08/11/2009 | US7572450 Composition for preventing cell death and/or tissue necrosis resulting from contact with neural thread proteins |
| 08/11/2009 | US7572446 Antagonists of HMG1 for treating inflammatory conditions |
| 08/11/2009 | US7572442 Selected antibody compositions for binding to aminophospholipids |
| 08/11/2009 | US7572438 Mutant having uracil phosphoribosyl transferase activity |
| 08/11/2009 | CA2487033C Amide substituted xanthine derivatives with gluconeogenesis modulating activity |
| 08/11/2009 | CA2449402C Substituted tetrahydroisoquinolines for use in the treatment of inflammatory diseases |
| 08/11/2009 | CA2448825C Pharmaceutical compositions of adsorbates of amorphous drug |
| 08/11/2009 | CA2447614C A method of implanting heavy metal such as nobel metal, e.g. gold, and metal for use in implantation |
| 08/11/2009 | CA2417590C Prophylactic or ameliorative agent for insulin resistance and/or obesity |
| 08/11/2009 | CA2375378C Antilipemic combinations comprising hmg-coa reductase inhibitors and carnitines |
| 08/11/2009 | CA2368688C Novel inhibitors of formation of advanced glycation endproducts (age's) |
| 08/11/2009 | CA2367410C Novel process for the preparation of 1-phenyl-2-(2-piridyl)ethanamine |
| 08/11/2009 | CA2359772C Cyclic substituted fused pyrrolocarbazoles and isoindolones |
| 08/11/2009 | CA2348732C Human h37 proteins and cdnas encoding the same |
| 08/11/2009 | CA2331393C Fatty acid analogues for the treatment of primary and secondary restenosis |
| 08/11/2009 | CA2321263C Use of bacteria endowed with arginine deiminase to induce apoptosis and/or reduce an inflammatory reaction and pharmaceutical or dietetic compositions containing such bacteria |
| 08/11/2009 | CA2320120C Benzisoxazole derivatives having d4-antagonistic activity |
| 08/11/2009 | CA2258503C Lectin compositions and uses thereof |
| 08/11/2009 | CA2241572C Apo-2 ligand |
| 08/06/2009 | WO2009097486A1 OXAZOLE-PYRROLE-PIPERAZINE α-HELIX MIMETIC |
| 08/06/2009 | WO2009097113A2 Oxazole and thiazole compounds as b-catenin modulators and uses thereof |
| 08/06/2009 | WO2009096581A1 Membrane fusion inhibitor |
| 08/06/2009 | WO2009096579A1 Nutritional composition for prevention of hyperglycemia |
| 08/06/2009 | WO2009096559A1 Method for production of orally rapidly disintegrating tablet comprising imidafenacin as active ingredient |